A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele
Clinical trial NCT04135495 · COMPLETED
Trial details
- NCT number
- NCT04135495
- Sponsor
- Eloxx Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-25
- Primary completion
- 2022-10-03
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.